U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07947043) titled 'Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection' on Jan. 16.
Brief Summary: This study is a single - center, single - arm, open - label, single - dose, dose - escalation exploratory study. The main purpose is to evaluate the safety and tolerability of autologous tumor - infiltrating lymphocyte injection in the treatment of recurrent or metastatic lung cancer or cervical cancer. Meanwhile, it will also preliminarily explore the effectiveness, PK characteristics, PD characteristics and changes in immune - related parameters of autologous tumor - infiltrating lymphocyte injection in subjects with...